Testimony Before the FDA’s Bone, Reproductive and Urologic Drugs Advisory Committee Regarding Hydroxyprogesterone Caproate (Makena)
View complete testimony as PDF
In a testimony before the Food and Drug Administration’s (FDA’s) Bone, Reproductive and Urologic Drugs Advisory Committee, Public Citizen urged the committee to recommend that the FDA withdraw hydroxyprogesterone caproate (Makena) from the market because there is a lack of substantial evidence demonstrating that the drug is effective for preventing preterm birth or complications of preterm birth.
See Public Citizen’s other work on hydroxyprogesterone caproate (Makena).